Rocket


Overview
Financials
News + Filings
Key Docs
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Tango Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Form of Pre-Funded Warrant",
"Securities Purchase Agreement, by and among Tango Therapeutics, Inc. and the parties named therein",
"Tango Therapeutics Announces $80 million Private Placement Financing"
08/07/2023 8-K Quarterly results
Docs: "Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Collaboration revenue 9,598 5,771 15,364 11,529 License revenue 5,000 — 5,000 — Total revenue 14,598 5,771 20,364 11,529 Operating expenses: Research and development 28,671 23,741 56,710 48,071 General and administrative 9,174 7,232 17,188 14,039 Total operating expenses 37,845 30,973 73,898 62,110 Loss from operations Other income, net 2,601 347 4,880 518 Provision for income taxes Net loss $ $ $ $ Net loss per common share – basic and diluted $ $ $ $ Weighted average number of common shares outstanding – basic and diluted 88,354,590 87,839,804 88,281,368 87,775,440 Condensed Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equ..."
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/09/2023 8-K Quarterly results
Docs: "Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Total revenue 5,766 5,758 Operating expenses: Research and development 28,039 24,330 General and administrative 8,013 6,807 Total operating expenses 36,052 31,137 Loss from operations Other income, net 2,278 171 Net loss $ $ Net loss per common share – basic and diluted $ $ Weighted average number of common shares outstanding – basic and diluted 88,193,917 87,670,653 Condensed Consolidated Balance Sheets March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 57,252 $ 59,968 Marketable securities 276,387 306,165 Accounts receivable — 2,000 Restricted cash — 567 Prepaid expenses and other current assets 9,361 6,572 Total current assets 343,000 375,272 Property and equipment, net 11,106 ..."
03/27/2023 8-K Quarterly results
Docs: "Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenue 6,411 5,716 24,860 37,042 Operating expenses: Research and development 29,091 21,634 105,906 77,636 General and administrative 7,887 6,066 30,025 17,596 Total operating expenses 36,978 27,700 135,931 95,232 Loss from operations Other income, net 1,558 115 2,949 247 Loss before income taxes Provision for income taxes Net loss $ $ $ $ Net loss per common share – basic and diluted $ $ $ $ Weighted average number of common shares outstanding – basic and diluted 87,971,485 87,567,676 87,820,037 62,108,032 Consolidated Balance Sheets December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 59,968 $ 142,745 Marketable securities 306,165 342,510 Acc..."
02/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development"
08/10/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights"
11/09/2021 8-K Quarterly results
Docs: "Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights"
04/14/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Agreement and Plan of Merger, by and among BCTG Acquisition Corp., BCTG Merger Sub Inc. and Tango Therapeutics, Inc",
"Form of Subscription Agreement, by and among BCTG Acquisition Corp. and certain institutional and accredited investors",
"Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies",
"INVESTOR PRESENTATION DATED APRIL 14, 2021"
10/07/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/14/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Balance Sheet"
09/09/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Underwriting Agreement, by and between the Registrant and SVB Leerink LLC, as representative of the several underwriters",
"Amended and Restated Certificate of Incorporation of the Company",
"Letter Agreement, by and among the Registrant and its officers, directors and initial stockholders",
"Investment Management Trust Agreement, by and between the Registrant and Continental Stock Transfer & Trust Company, LLC as trustee",
"Escrow Agreement, by and among the Registrant, Continental Stock Transfer & Trust Company, LLC, as escrow agent, and the Registrant’ s initial stockholders",
"Registration Rights Agreement, by and among the Registrant, Continental Stock Transfer & Trust Company, LLC, and the Registrant’ s initial stockholders",
"Subscription Agreement, by and between the Registrant and the Sponsor",
"Administrative Support Agreement, by and between the Registrant and Boxer Capital, LLC, an affiliate of the Sponsor",
"Indemnity Agreements, each dated September 2, 2020, by and between the Registrant and each of the Registrant’ s officers and directors",
"BCTG Acquisition Corp., Sponsored by Boxer Capital, LLC, Announces Closing of $166.8 Million Initial Public Offering, Including the Full Exercise of the Underwriter’ s Option to Purchase Additional Shares"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy